A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
|Videos|February 4, 2021
The COVID-19 Pandemic May Cause a Long-Term Disruption to Cancer Care
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers, about how the COVID-19 pandemic is going to impact cancer mortality.
Advertisement
Pharmacy Times® interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers and medical director at Ann B. Barshinger Cancer Institute, Penn Medicine in Lancaster PA about how the coronavirus disease 2019 (COVID-19) pandemic is going to impact cancer mortality.
The full conversation can be found in the video above.
Advertisement
Related to this article
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
4
Glucose Monitoring: Timing Makes Every Reading Count
5